148 related articles for article (PubMed ID: 34871120)
1. Reduced calcineurin inhibitor exposure with antibody induction and recurrent hepatocellular carcinoma after liver transplantation.
Abrahamsson J; Sternby Eilard M; Rizell M; Bennett W; Åberg F
Scand J Gastroenterol; 2022 Mar; 57(3):325-332. PubMed ID: 34871120
[TBL] [Abstract][Full Text] [Related]
2. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
Rodríguez-Perálvarez M; Tsochatzis E; Naveas MC; Pieri G; García-Caparrós C; O'Beirne J; Poyato-González A; Ferrín-Sánchez G; Montero-Álvarez JL; Patch D; Thorburn D; Briceño J; De la Mata M; Burroughs AK
J Hepatol; 2013 Dec; 59(6):1193-9. PubMed ID: 23867318
[TBL] [Abstract][Full Text] [Related]
3. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
5. Trough Levels of Everolimus Are Associated With Recurrence Rates of Hepatocellular Carcinoma After Liver Transplantation.
Cholongitas E; Antoniadis N; Goulis I; Theocharidou E; Ιmvrios G; Giouleme O; Filis D; Mouloudi E; Akriviadis E; Fouzas I
Transplant Proc; 2019 Mar; 51(2):450-453. PubMed ID: 30879564
[TBL] [Abstract][Full Text] [Related]
6. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
7. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
8. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
9. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
10. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation.
Lee JY; Kim YH; Yi NJ; Kim HS; Lee HS; Lee BK; Kim H; Choi YR; Hong G; Lee KW; Suh KS
Clin Mol Hepatol; 2014 Jun; 20(2):192-203. PubMed ID: 25032186
[TBL] [Abstract][Full Text] [Related]
11. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
12. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation.
Guerrini GP; Pinelli D; Di Benedetto F; Marini E; Corno V; Guizzetti M; Aluffi A; Zambelli M; Fagiuoli S; Lucà MG; Lucianetti A; Colledan M
Surg Oncol; 2016 Dec; 25(4):419-428. PubMed ID: 26403621
[TBL] [Abstract][Full Text] [Related]
15. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium.
Tran BV; Moris D; Markovic D; Zaribafzadeh H; Henao R; Lai Q; Florman SS; Tabrizian P; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Hoteit M; Levine MH; Cillo U; Vitale A; Verna EC; Halazun KJ; Tevar AD; Humar A; Chapman WC; Vachharajani N; Aucejo F; Lerut J; Ciccarelli O; Nguyen MH; Melcher ML; Viveiros A; Schaefer B; Hoppe-Lotichius M; Mittler J; Nydam TL; Markmann JF; Rossi M; Mobley C; Ghobrial M; Langnas AN; Carney CA; Berumen J; Schnickel GT; Sudan DL; Hong JC; Rana A; Jones CM; Fishbein TM; Busuttil RW; Barbas AS; Agopian VG
Liver Transpl; 2023 Jul; 29(7):683-697. PubMed ID: 37029083
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Grigg SE; Sarri GL; Gow PJ; Yeomans ND
Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
[TBL] [Abstract][Full Text] [Related]
19. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation.
Rodríguez-Perálvarez M; Colmenero J; González A; Gastaca M; Curell A; Caballero-Marcos A; Sánchez-Martínez A; Di Maira T; Herrero JI; Almohalla C; Lorente S; Cuadrado-Lavín A; Pascual S; López-Garrido MÁ; González-Grande R; Gómez-Orellana A; Alejandre R; Zamora-Olaya J; Bernal-Bellido C;
Am J Transplant; 2022 Jun; 22(6):1671-1682. PubMed ID: 35286761
[TBL] [Abstract][Full Text] [Related]
20. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
